发明授权
US07226601B1 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
失效
修饰的超抗原和寻靶化合物之间的缀合以及缀合物的使用
- 专利标题： Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
- 专利标题（中）： 修饰的超抗原和寻靶化合物之间的缀合以及缀合物的使用
-
申请号： US08765695申请日： 1995-06-07
-
公开(公告)号： US07226601B1公开(公告)日： 2007-06-05
- 发明人: Lars Abrahmsen , Per Bjork , Mikael Dohlsten , Terje Kalland
- 申请人： Lars Abrahmsen , Per Bjork , Mikael Dohlsten , Terje Kalland
- 申请人地址： SE Lund
- 专利权人： Active Biotech AB
- 当前专利权人： Active Biotech AB
- 当前专利权人地址： SE Lund
- 代理机构： Fulbright & Jaworski LLP
- 优先权： SE9402430 19940711
- 国际申请： PCT/SE95/00681 WO 19950607
- 国际公布： WO96/01650 WO 19960125
- 主分类号： C07K16/46
- IPC分类号： C07K16/46 ; C07K19/00 ; A61K39/395
摘要：
A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococcal enterotoxin A, binds to a Vβ of a T cell receptor, and has a D227A mutation so that the peptide has a modified ability to bind to MHC class II antigens.
信息查询
